No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Mesoblast Set To File BLA For Ryoncil With FDA Next Week
Mesoblast to Submit FDA Application for Ryoncil in Treating Pediatric GVHD
High Insider Ownership Growth Stocks On The ASX In June 2024
Cantor Fitzgerald Reiterates Overweight on Mesoblast
Mesoblast Analyst Ratings
Mesoblast Targets FDA Approval With Ryoncil